摘要
目的:观察福善美对绝经后骨质疏松症患者血清骨保护素水平及骨密度的影响,进一步探讨福善美治疗绝经后骨质疏松症的机理。方法:将符合要求的82例患者随机分为2组,治疗组42例,对照组40例。治疗组患者口服福善美、阿法迪三及钙尔奇D;对照组患者口服阿法迪三和钙尔奇D。分别于治疗前、治疗6个月、治疗12个月时测定患者的血清骨保护素水平和骨密度。结果:①2组之间血清骨保护素水平比较,差异有统计学意义(F=4.793,P=0.031)。时间因素与处理方法存在交互效应(F=90.608,P=0.000)。不同的时间点之间存在时间效应(F=48.717,P=0.000);治疗组治疗6个月及治疗12个月时血清骨保护素水平低于治疗前(P=0.000,P=0.000);对照组治疗6个月及治疗12个月时血清骨保护素水平与治疗前相比,差异无统计学意义(P=0.375,P=0.120)。治疗组血清骨保护素水平呈逐渐下降趋势,而对照组无显著变化。②2组之间骨密度比较,差异有统计学意义(F=4.092,P=0.046)。时间因素与处理方法存在交互效应(F=48.361,P=0.000)。不同的时间点之间存在时间效应(F=29.826,P=0.000);治疗组治疗6个月及治疗12个月时骨密度高于治疗前(P=0.000,P=0.000);对照组治疗6个月及治疗12个月时骨密度与治疗前相比,差异无统计学意义(P=1.000,P=0.830)。治疗组骨密度呈逐渐升高趋势,而对照组无显著变化。结论:福善美可降低绝经后骨质疏松患者血清骨保护素水平,明显增加骨密度。福善美治疗绝经后骨质疏松症的机理可能是它能直接和间接抑制破骨细胞活性。
Objective：To observe the effect of Fosamax on serum osteoprotegerin level and bone density in patients with postmenopausal osteoporosis,and make further study on the mechanism of Fosamax in the treatment of postmenopausal osteoporosis.Methods：82 patients met the criterion were randomly divided into 2 groups,42 cases in the treatment group,while the others in the control group.Patients in the treatment group were administrated with Fosamax,Alpha D3 and Caltrate D,while the others in the control group were administrated with Alpha D3 and Caltrate D only.Serum osteoprotegerin level and bone density of the patients were measured before the treatment,after treatment for 6 months and 12 months respectively.Results：①There was statistical difference in the serum osteoprotegerin level between the 2 groups（F=4.793,P=0.031）,and there was interaction effects between time factor and treatment process（F=90.608,P=0.000）.There was time effects between different time（F=48.717,P=0.000）.For the patients in the treatment group,serum osteoprotegerin levels after treatment for 6 months and 12 months were lower than those before the treatment（P=0.000,P=0.000）.For the patients in the control group,there was no statistical difference in the serum osteoprotegerin levels between the 6th month,12th month after the treatment and before the treatment（P=0.375,P=0.120）.Serum osteoprotegerin levels of patients reduced significantly in the treatment group,compared with no significant changes of those in the control group.②There was statistical difference in the bone density between the 2 groups（F=4.092,P=0.046）,and there was interaction effects between time factor and treatment process（F=48.361,P=0.000）.There was time effects between different time（F=29.826,P=0.000）.For the patients in the treatment group,bone density after treatment for 6 months and 12 months were higher than those before the treatment（P=0.000,P=0.000）.For the control group,there was no statistical difference in the bone density betw
出处
《中医正骨》
2011年第6期16-19,共4页
The Journal of Traditional Chinese Orthopedics and Traumatology
基金
浙江省中医管理局中医(中西医结合)单病种诊疗规范研究项目(2008GA014)
关键词
骨质疏松
绝经后
二膦酸盐类
骨密度
骨保护素
Key words Osteoporosis
Postmenopausal
Diphosphonates
Bone density
Osteoprotegerin
